drugset
drugset / Trial / NCT03339752

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

NCT03339752 ↗

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin

Timeline

Start
2017-10-30
Primary completion
2017-12-02
Completion
2017-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg —
Subject Rosuvastatin Small molecule 10 mg —

Indications

No indication recorded.